Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,795 GBp
Change Today 0.00 / 0.00%
Volume 15.2K
HCM On Other Exchanges
Symbol
Exchange
London
OTC US
As of 12:19 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

hutchison china meditech ltd (HCM) Snapshot

Open
1,795 GBp
Previous Close
1,795 GBp
Day High
1,795 GBp
Day Low
1,795 GBp
52 Week High
05/27/15 - 2,003 GBp
52 Week Low
10/13/14 - 1,055 GBp
Market Cap
1.0B
Average Volume 10 Days
23.2K
EPS TTM
0.02 GBp
Shares Outstanding
56.5M
EX-Date
--
P/E TM
1,237.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for HUTCHISON CHINA MEDITECH LTD (HCM)

Related News

No related news articles were found.

hutchison china meditech ltd (HCM) Related Businessweek News

No Related Businessweek News Found

hutchison china meditech ltd (HCM) Details

Hutchison China MediTech Limited engages in the research, development, manufacture, and sale of pharmaceuticals and health oriented consumer products primarily in the People’s Republic of China. It operates through three segments: China Healthcare, Drug Research and Development, and Consumer Products. The company manufactures, distributes, and sells over-the-counter, prescription, and health supplements products under the Bai Yun Shan and Shang Yao brands; and offers drug research and development services. It also offers traditional Chinese medicine products in cardiovascular and cold/flu therapeutic areas. In addition, the company develops clinical drug candidates, including HMPL-004 that is in Phase III clinical trials for ulcerative colitis and Crohn’s disease; Fruquintinib, which is in Phase III clinical trial for the treatment of colorectal, non-small cell lung, and gastric cancer; and Sulfatinib, a Phase 1b clinical trial product for neuroendocrine tumours, as well as Epitinib for treating non-small cell lung cancer. Further, it offers Theliatinib, a Phase I clinical trial product for the treatment of solid tumours; AZD6094 that is in Phase 1b clinical trial for treating non-small cell lung and gastric cancer; HMPL-523 and HMPL-689, which are preclinical stage products for the treatment of hematological cancers; and HMPL-453 that is in preclinical stage for the treatment of solid tumours. The company also offers organic and natural food, beverage, baby, and beauty care products; and distributes organic and natural products. Hutchison China MediTech Limited has strategic collaborations with multinational pharmaceutical and healthcare companies, including AstraZeneca AB (Publ); Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; and Nestlé Health Science SA. The company was founded in 2000 and is based in Hong Kong, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.

Founded in 2000

hutchison china meditech ltd (HCM) Top Compensated Officers

Chief Executive Officer, Executive Director, ...
Total Annual Compensation: $944.8K
Chief Financial Officer and Executive Directo...
Total Annual Compensation: $472.0K
Compensation as of Fiscal Year 2014.

hutchison china meditech ltd (HCM) Key Developments

Hutchison China MediTech Ltd. Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2015

Hutchison China MediTech Ltd. announced unaudited consolidated earnings results for the six months ended June 30, 2015. For the period, the company's revenue was $65.722 million compared with $30.329 million a year ago. Operating profit was $4.606 million compared with $8.068 million a year ago. Profit before taxation was $3.899 million compared with $7.324 million a year ago. Profit for the period from continuing operations was $2.738 million compared with $6.37 million a year ago. Profit for the period was $2.738 million compared with $8.12 million a year ago. Profit attributable to equity holders of the company from continuing operations was $2.297 million or $0.0430 per diluted share compared with $5.573 million or $0.1059 per diluted share a year ago. Profit attributable to equity holders of the company was $2.738 million or $0.043 per diluted share compared with $8.12 million or $0.1225 per diluted share a year ago. Net cash generated from operating activities was $0.443 million compared with $14.824 million a year ago. Purchase of property, plant and equipment was $1.446 million compared with $1.866 million a year ago. The company revenues were driven mainly by a full period of consolidation of Hutchison Sinopharm, which began operations in second quarter of 2014.

Hutchison China MediTech Ltd. to Report First Half, 2015 Results on Jul 28, 2015

Hutchison China MediTech Ltd. announced that they will report first half, 2015 results on Jul 28, 2015

Hutchison China MediTech Ltd., H1 2015 Earnings Call, Jul 28, 2015

Hutchison China MediTech Ltd., H1 2015 Earnings Call, Jul 28, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HCM:LN 1,795.00 GBp 0.00

HCM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HCM.
View Industry Companies
 

Industry Analysis

HCM

Industry Average

Valuation HCM Industry Range
Price/Earnings 100.0x
Price/Sales 11.4x
Price/Book 14.8x
Price/Cash Flow 1,265.5x
TEV/Sales 12.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HUTCHISON CHINA MEDITECH LTD, please visit www.chi-med.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.